These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 16585951)

  • 1. Harnessing preclinical mouse models to inform human clinical cancer trials.
    Gutmann DH; Hunter-Schaedle K; Shannon KM
    J Clin Invest; 2006 Apr; 116(4):847-52. PubMed ID: 16585951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conditional mouse models of cancer.
    Vignjevic D; Fre S; Louvard D; Robine S
    Handb Exp Pharmacol; 2007; (178):263-87. PubMed ID: 17203659
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective.
    Singh M; Johnson L
    Clin Cancer Res; 2006 Sep; 12(18):5312-28. PubMed ID: 17000664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical predictors of clinical safety: opportunities for improvement.
    Sistare FD; DeGeorge JJ
    Clin Pharmacol Ther; 2007 Aug; 82(2):210-4. PubMed ID: 17507920
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of animal models for identification of potential therapeutics for rheumatoid arthritis.
    Hegen M; Keith JC; Collins M; Nickerson-Nutter CL
    Ann Rheum Dis; 2008 Nov; 67(11):1505-15. PubMed ID: 18055474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New therapeutic advances in the management of progressive thyroid cancer.
    Woyach JA; Shah MH
    Endocr Relat Cancer; 2009 Sep; 16(3):715-31. PubMed ID: 19218279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving the evaluation of new cancer treatments: challenges and opportunities.
    Rothenberg ML; Carbone DP; Johnson DH
    Nat Rev Cancer; 2003 Apr; 3(4):303-9. PubMed ID: 12671669
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical models for pediatric solid tumor drug discovery: current trends, challenges and the scopes for improvement.
    Kumar S; Mokhtari RB; Yeger H; Baruchel S
    Expert Opin Drug Discov; 2012 Nov; 7(11):1093-106. PubMed ID: 22998522
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticle therapeutics: an emerging treatment modality for cancer.
    Davis ME; Chen ZG; Shin DM
    Nat Rev Drug Discov; 2008 Sep; 7(9):771-82. PubMed ID: 18758474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biological surrogate end-points in cancer trials: potential uses, benefits and pitfalls.
    Cooper R; Kaanders JH
    Eur J Cancer; 2005 Jun; 41(9):1261-6. PubMed ID: 15939261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Some thoughts on experimental screening.
    Carter SK
    Biomedicine; 1975 Jan; 22(1):5-17. PubMed ID: 1101978
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular markers and targets for colorectal cancer prevention.
    Janakiram NB; Rao CV
    Acta Pharmacol Sin; 2008 Jan; 29(1):1-20. PubMed ID: 18158862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Considerations for the sensible use of rodent models of inflammatory disease in predicting efficacy of new biological therapeutics in the clinic.
    Arnett HA; Viney JL
    Adv Drug Deliv Rev; 2007 Sep; 59(11):1084-92. PubMed ID: 17804112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Faithful companions: a proposal for neurooncology trials in pet dogs.
    Kimmelman J; Nalbantoglu J
    Cancer Res; 2007 May; 67(10):4541-4. PubMed ID: 17510377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Forty years of cancer modelling in the mouse.
    Hirst GL; Balmain A
    Eur J Cancer; 2004 Sep; 40(13):1974-80. PubMed ID: 15315806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.
    Man S; Munoz R; Kerbel RS
    Cancer Metastasis Rev; 2007 Dec; 26(3-4):737-47. PubMed ID: 17846863
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Guidelines for the preclinical in vivo evaluation of pharmacological active drugs for ALS/MND: report on the 142nd ENMC international workshop.
    Ludolph AC; Bendotti C; Blaugrund E; Hengerer B; Löffler JP; Martin J; Meininger V; Meyer T; Moussaoui S; Robberecht W; Scott S; Silani V; Van Den Berg LH;
    Amyotroph Lateral Scler; 2007 Aug; 8(4):217-23. PubMed ID: 17653919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in molecular carcinogenesis: current and future use of mouse models to screen and validate molecularly targeted anticancer drugs.
    Frijhoff AF; Conti CJ; Senderowicz AM
    Mol Carcinog; 2004 Apr; 39(4):183-94. PubMed ID: 15057870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Preclinical data as basis for the design of clinical studies].
    Fichtner I
    Onkologie; 2008; 31 Suppl 2():34-8. PubMed ID: 18487867
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Extrapolation of experimental data on the methods for the clinical evaluation of drugs].
    Karkishchenko NN
    Farmakol Toksikol; 1982; 45(3):22-7. PubMed ID: 7095124
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.